Survival and hospitalization in heart failure patients with or without diabetes treated with β-blockers

Journal of Cardiac Failure

Volumn 9, Issue 3, 2003, Pages 192-202

  Bobbio, Marco ^a,d   Ferrua, Stefania ^a   Opasich, Cristina ^b   Porcu, Maurizio ^c   Lucci, Donata ^d   Scherillo, Marino ^e   Tavazzi, Luigi ^f   Maggioni, Aldo Pietro ^d  

^a Policlinico MultiMedica   (Italy)

^b IRCCS   (Italy)

^c BROTZU HOSPITAL   (Italy)

^d ANMCO RESEARCH CENTER   (Italy)

^e MONALDI HOSPITAL   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Beta blockers; Diabetes mellitus; Mortality; Outcome research

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; METOPROLOL; NITRATE; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SURVIVAL;

EID: 0038274729     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2003.31     Document Type: Article

References (35)

1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol 1974;34:29-34.
2. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001;249:225-35.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999;159:29-34.
4. Amato L, Paolisso G, Cacciatore F, Ferrara N, Ferrara P, Canonico S, et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997;23:213-8.
5. Polanczyk CA, Rohde LEP, Dec GW, DiSalvo T. Ten-year trends in hospital care for congestive heart failure. Improved outcomes and increased use of resources. Arch Intern Med 2000;160:325-32.
6. Fabbri G, Ambrosio G, Cafiero M, Caputo F, Lavecchia R, Loru F, et al., on behalf of TEMISTOCLE Investigators. In-hospital outcomes of patients with heart failure by ward of admission: the TEMISTOCLE registry (abstract). Eur J Heart Failure Suppl 2002;1:56.
7. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology, Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
8. American College of Cardiology/American Heart Association Task Force on practice guidelines. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol 2001;38:2101-13.
9. MacLeod MJ, McLay J. Drug treatment of hypertension complicating diabetes mellitus. Drugs 1998;56:189-202.
10. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL for the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12.
11. Joint National Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
12. Maggioni AP, Tavazzi L. Introducing new treatments in clinical practice: the Italian approach to β blockers in heart failure. Heart 1999;81:453-4.
13. Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989;7:551-9.
14. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Pressure 1992;1:92-101.
15. Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med 1996;101:33S-46S.
16. Micossi P, Pollavini G, Raggi U, Librenti MC, Garimberti B, Beggi P. Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus. Horm Metab Res 1984;16:59-63.
17. Beta-Blocker Heart Attack Trial research group (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-14.
18. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reaction to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1981;2:539-43.
19. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989;298:1152-7.
20. Lager I, Blohme G, Smith U. Effects of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin dependent diabetes. Lancet 1979;1:458-62.
21. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991;14:39-47.
22. Prisant LM, Carr AA. Antihypertensive drug therapy and insulin resistance. Am J Hypertens 1992;5:775-7.
23. Haenni A, Lithell H. Treatment with a betablocker with β2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994;43:455-61.
24. Swislocki ALM. Impaired insulin clearance in essential hypertension. J Hum Hypertens 1994;8:185-90.
25. De Fronzo RA, Ferrannini E. Insulin resistance a multifaceted syndrome responsible for NIDDM, obesity, hypertension, and dyslipidemia. Diabetes Care 1991;14:173-7.
26. Broadstone VL, Pfeifer MA, Bajaj V, Stagner JI, Samols E. Alpha adrenergic blockade improves glucose potentiated insulin secretion in non insuline dependent diabetes mellitus. Diabetes 1978;36:932-7.
27. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two-beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14:489-94.
28. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955-9.
29. Gajdoš M, Spustová V, Šmid J, Opatrný J, Dzúrik R. Carvedilol does not impair insulin sensitivity and plasma lipid levels. Eur Heart J 1996;17:343.
30. Lithell H, Andersson PE. Metabolic effects of carvedilol in hypertensive patients. Eur J Clin Pharmacol 1997;52:13-7.
31. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14:489-94.
32. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - a randomized, controlled trial. Ann Intern Med 1997;126:955-9.
33. Agrawal B, Stienen U. Long-term effect of carvedilol on lipids and blood glucose: a metaanalysis approach. Can J Cardiol 1995;11:62D.
34. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302.
35. Zuanetti G, Latini R. Impact of pharmacological treatment on mortality after acute myocardial infarction in diabetic patients. J Diabetes Complications 1997;11:131-6.